Alseres Pharmaceuticals, Inc.'s Chairman, Peter Savas, Reviews Company's Progress in its Annual Letter to Stockholders
ls Inc. ...Contact: ...Sharon Correia -- 508-497-2360 ext. 224 ...Alseres Pharmaceuticals Inc. ... scorreia@alseres.com ...
Date:6/12/2008
ls, Inc.
Contact:
Sharon Correia -- 508-497-2360 ext. 224
Alseres Pharmaceuticals, Inc.
scorreia@alseres.com
Adam Friedman -- 212-981-2529 ext. 18
Adam Friedman Associates
adam@adam-friedman.com
'/>"/>SOURCE Alseres Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine news :1.
Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference2.
Alseres Pharmaceuticals, Inc. Raises $5 Million3.
Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K4.
Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference5.
Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call6.
Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results7.
Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)8.
Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting9.
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma10.
Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference11.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.